PF-06747775
CAS No. 1776112-90-3
PF-06747775( PF 06747775 | PF06747775 | PF 6747775 )
Catalog No. M12674 CAS No. 1776112-90-3
A potent, selective, irreversible EGFR mutants with IC50 of 12, 3, 4 and 5 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
25MG | 656 | Get Quote |
|
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePF-06747775
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, irreversible EGFR mutants with IC50 of 12, 3, 4 and 5 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively.
-
DescriptionA potent, selective, irreversible EGFR mutants with IC50 of 12, 3, 4 and 5 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively; displays excellent selectivity over wild-type EGFR (IC50=307 nM), and desirable ADME properties, shows potential for treatment of EGFR T790M mutation in advanced NSCLC.Lung Cancer Phase 2 Clinical.
-
In VitroMavelertinib exhibits selectivity over wild-type EGFR (IC50=307 nM).Mavelertinib (10 μM) exhibits less than 50% e?ect or inhibition against all nonkinase targets.Mavelertinib inhibits the hERG26 current with an IC50 > 100 μM.
-
In VivoMavelertinib exhibits low to moderate oral bioavailability (mouse 60%, rat 11%, dog 66%) following oral administration (mouse 1, rat 30, dog 3 mg/kg).Mavelertinib exhibits short plasma half-lives (mouse 0.56, rat 0.28, dog 1.3 h) due to moderate to high plasma clearance (mouse 53, rat 49, dog 12 mL/min/kg) and low steady-state volume of distribution (mouse 1.48, rat 0.66, dog 0.94 L/kg) following intravenous administration (1 mg/kg to mouse, rat and dog). Animal Model:Female Nu/Nu mice Dosage:1 mg/kg (Pharmacokinetic Analysis) Administration:P.o. and i.v. administration Result:Oral bioavailability (60%), T1/2 (1.48 h).
-
SynonymsPF 06747775 | PF06747775 | PF 6747775
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number1776112-90-3
-
Formula Weight415.433
-
Molecular FormulaC18H22FN9O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 47.5 mg/mL (114.34 mM)
-
SMILESC=CC(N[C@@H]1CN(C2=NC(NC3=CN(C)N=C3OC)=C4N=CN(C)C4=N2)C[C@H]1F)=O
-
Chemical NameN-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Planken S, et al. J Med Chem. 2017 Apr 13;60(7):3002-3019.
2. Patel H, et al. Eur J Med Chem. 2017 May 11. pii: S0223-5234(17)30388-4.
3. Wang S, et al. J Hematol Oncol. 2016 Apr 12;9:34.
molnova catalog
related products
-
Ticlopidine
Ticlopidine is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor.
-
Varlitinib
Varlitinib is a selective and potent ErbB1(EGFR) and ErbB2(HER2) inhibitor with IC50 of 7 nM and 2 nM respectively. Phase 2.
-
WZ4002
WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.